| Literature DB >> 28122491 |
Zhen-Feng Zhou1, Xiu-Ping Jia1,2, Kai Sun1, Feng-Jiang Zhang1, Li-Na Yu1, Tian Xing1, Min Yan3.
Abstract
BACKGROUND: Perioperative allogenic transfusion is required in almost 50% of patients undergoing cardiac surgery and is associated with higher risk of mortality and morbidity (Xue et al., Lancet 387:1905, 2016; Ferraris et al., Ann Thorac Surg 91:944-82, 2011). Acute normovolemic hemodilution (ANH) is recommended as a potential strategy during cardiac surgery, but the blood conservation effect and the degree of ANH was still controversial. There is also an increasing concern about the improved outcomes associated with ANH. Therefore, a better understanding of the effect of mild volume ANH during cardiac surgery is urgently needed.Entities:
Keywords: Cardiac surgery; Complication; Hemodilution; Transfusion
Mesh:
Year: 2017 PMID: 28122491 PMCID: PMC5267449 DOI: 10.1186/s12871-017-0305-7
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.217
Demographic and Clinical characteristics of the two study groups before and after propensity score matching
| Entire sample | Propensity-matched group | |||||
|---|---|---|---|---|---|---|
| Preoperative characteristics | ANH |
| ANH |
| ||
| Yes ( | No ( | Yes ( | No ( | |||
| Age [median (SD); yr] | 50 ± 12 | 51 ± 13 | 0.139 | 50 ± 12 | 50 ± 13 | 0.866 |
| Male/female, no.(%) | 224/134 (62.6%) | 394/537 (42.3%) | <0.001 | 220/134 (62.1%) | 222/132 (62.7%) | 0.877 |
| Height [median (SD); cm] | 164 ± 7 | 162 ± 7 | <0.001 | 164 ± 7 | 164 ± 7 | 0.761 |
| Weight [mean (SD); kg] | 63 ± 10 | 60 ± 10 | <0.001 | 63 ± 10 | 62 ± 10 | 0.580 |
| Estimated blood volume [mean (SD); mL] | 4298 ± 779 | 4045 ± 722 | <0.001 | 4285 ± 765 | 4258 ± 750 | 0.636 |
| ASA, no. (%) | 0.070 | 0.230 | ||||
| I | 1 (0.3%) | 4 (0.4) | 1 (0.3%) | 3 (0.8%) | ||
| II | 79 (22.1%) | 206 (22.1%) | 79 (22.3%) | 77 (21.8%) | ||
| III | 248 (69.3%) | 678 (72.8%) | 244 (68.9%) | 256 (72.3%) | ||
| IV | 30 (8.4%) | 43 (46%) | 30 (8.5%) | 18 (5.1%) | ||
| NYHA class III/IV, no.(%) | 83 (23.2%) | 233 (25%) | 0.491 | 81 (22.9%) | 75 (21.2%) | 0.586 |
| History of smoking, no. (%) | 108 (30.2%) | 204 (21.9%) | 0.002 | 108 (30.5%) | 100 (28.2%) | 0.509 |
| Coexistent disease | ||||||
| AF, no. (%) | 81 (22.6%) | 222 (23.8%) | 0.644 | 80 (22.6%) | 82 (23.2%) | 0.858 |
| Hypertension, no. (%) | 75 (20.9%) | 209 (22.4%) | 0.561 | 74 (20.9%) | 79 (22.3%) | 0.648 |
| Diabetes, no. (%) | 17 (4.7%) | 63 (6.8%) | 0.179 | 17 (4.8%) | 18 (5.1%) | 0.862 |
| HLP, no. (%) | 5 (1.4%) | 6 (0.6%) | 0.191 | 5 (1.4%) | 2 (0.6%) | 0.451 |
| Cerebrovascular disease, no. (%) | 16 (4.5) | 37 (4.0) | 0.688 | 16 (4.5) | 16 (4.5) | 1.000 |
| Preoperative Medication | ||||||
| ACEI and ARB, no. (%) | 28 (7.8%) | 77 (8.3%) | 0.792 | 28 (7.9%) | 29 (8.2%) | 0.890 |
| β-blockers, no. (%) | 19 (5.3%) | 66 (7.1%) | 0.248 | 19 (5.4%) | 22 (6.2%) | 0.629 |
| Calcium Channel Blockers, no. (%) | 25 (7.0%) | 71 (7.6%) | 0.694 | 24 (6.8%) | 19 (5.4%) | 0.431 |
| Diuretics, no. (%) | 16 (4.5%) | 70 (7.5%) | 0.049 | 16 (4.5%) | 13 (3.7%) | 0.569 |
| Preoperative laboratory examination | ||||||
| T-ch [median (SD); mmol/L] | 4.5 ± 1.0 | 4.4 ± 1.1 | 0.178 | 4.5 ± 1.0 | 4.4 ± 1.1 | 0.305 |
| Cr [median (SD); umol/L] | 70 ± 15 | 67 ± 16 | <0.001 | 70 ± 15 | 70 ± 17 | 0.976 |
| ALB [median (SD); g/L] | 42 ± 4 | 42 ± 4 | 0.182 | 42 ± 4 | 42 ± 4 | 0.535 |
| HCT [median (SD); %] | 42 ± 5 | 40 ± 4 | <0.001 | 42 ± 4 | 42 ± 4 | 0.918 |
| Propensity score [median (SD)] | 0.33 ± 0.12 | 0.26 ± 0.11 | <0.001 | 0.32 ± 0.12 | 0.32 ± 0.11 | 0.840 |
#: Fisher’s exact test was used; BMI body mass index, ASA American Society of Anesthesiologists, NYHA New York Heart Association, AF atrial fibrillation, HLP hyperlipidaemia, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, MI myocardial infarction in 30 days before operation, ARB angiotensin receptor blockers, ACEI angiotensin converting enzyme inhibitors, LVEF left ventricular ejection fraction, T-ch serum cholesterol, Cr serum creatinine, ALB albumin, HCT hematocrit
Fig. 1Study population recruitment summary. LVEF = left ventricular ejection fraction; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; INR = international normalized ratio; Plt = platelet count; ANH = acute normovolemic hemodilution
Operative Characteristics
| Characteristics | ANH | ||
|---|---|---|---|
| Yes ( | No ( |
| |
| ANH [mean (SD); mL] | 342 ± 138 | ||
| Operative Characteristics | |||
| Intra-aortic balloon pump, no. (%) | 1 (0.3%) | 1 (0.3%) | 1.000 |
| Duration of anesthesia [mean (SD); min] | 297 ± 98 | 305 ± 110 | 0.325 |
| Duration of surgery [mean (SD); min] | 252 ± 89 | 260 ± 110 | 0.244 |
| CPB time [mean (SD); min] | 125 ± 59 | 129 ± 63 | 0.399 |
| Type of surgery, no. (%) | 0.168 | ||
| CABG | 23 (6.5%) | 30 (8.5%) | |
| Valve surgery | 137 (38.7%) | 121 (34.2%) | |
| Complex cardiac surgery | 116 (32.8%) | 126 (35.6%) | |
| Aortic surgery | 24 (6.8%) | 13 (3.7%) | |
| Others surgery | 54 (15.3%) | 64 (18.1%) | |
| Input and Output | |||
| Blood loss [mean (SD); mL] | 684 ± 355 | 678 ± 514 | 0.855 |
| Urine output [mean (SD); mL] | 788 ± 465 | 730 ± 419 | 0.084 |
| Pump blood [mean (SD); mL] | 512 ± 129 | 508 ± 139 | 0.708 |
| Cell salvage [median (SD); mL] | 375 ± 267 | 369 ± 343 | 0.797 |
| Intraoperative cristalloids and colloids [mean (SD); mL] | 2272 ± 610 | 2140 ± 770 | 0.011 |
| Hemostatic drugs Characteristics | |||
| Tranexamic Acid, no. (%) | 121 (34.2%) | 113 (31.9%) | 0.523 |
| Prothrombin Complex Concentrate, no. (%) | 6 (1.7%) | 7 (20%) | 0.780 |
| Fibrinogen concentrate, no. (%) | 6 (1.7%) | 10 (2.8%) | 0.312 |
| Recombinant activated factor VII, no. (%) | 1 (0.3%) | 3 (0.8%) | 0.624 |
| Arterial blood gas analysis | |||
| Calcium content Pre-CPB [mean (SD); mmol/L] | 1.08 ± 0.10 | 1.08 ± 0.09 | 0.871 |
| Blood pH Pre-CPB [mean (SD)] | 7.40 ± 0.06 | 7.39 ± 0.05 | 0.636 |
| Hct Pre-CPB [mean (SD);%] | 38 ± 5 | 40 ± 5 | <0.001 |
| Calcium content End ± CPB [mean (SD); mmol/L] | 0.90 ± 0.13 | 0.87 ± 0.13 | 0.086 |
| Blood pH End-CPB [mean (SD)] | 7.48 ± 0.08 | 7.50 ± 0.09 | 0.055 |
| Hct End-CPB [mean (SD);%] | 25 ± 4 | 27 ± 5 | 0.003 |
| Calcium content Post ± CPB [mean (SD); mmol/L] | 1.03 ± 0.17 | 1.02 ± 0.15 | 0.628 |
| Blood pH Post-CPB [mean (SD)] | 7.37 ± 0.07 | 7.38 ± 0.08 | 0.168 |
| Hct Post ± CPB [mean (SD);%] | 29 ± 4 | 30 ± 5 | 0.021 |
#: Fisher’s exact test was used; CPB cardiopulmonary bypass, CABG coronary artery bypass grafting, Valve surgery aortic, mitral and tricuspid valve surgery without ascending aortic replacement, Complex cardiac surgery combined coronary artery bypass graft surgery and valve surgery or multi-valve surgery, Aortic surgery aortic dissections, type A and B, thoracic aortic aneurysms) or Aortic valve surgery with ascending aortic replacement; Others surgery type including atrial septal defect, interventricular septal defect, atrial myxoma, Aneurysm Sinus Valsalva, coronary artery pulmonary artery fistula, patent foramen ovale/atrial septal aneurysm surgery, and surgery for cardiac tumors, Pumped blood blood recovered from the extracorporeal circuit system, CPB cardiopulmonary bypass, Hb hemoglobin, Hct hematocrit, Pre-CPB before CPB and after performing ANH, End-CPB at the end of CPB, Post-CPB 30 min after CPB
Perioperative allogeneic transfusions
| Allogeneic transfusions | Propensity-matched | ||
|---|---|---|---|
| ANH | Non-ANH |
| |
| ( | ( | ||
| Intra-operative transfusion | |||
| RBC transfusion, no. (%) | 30 (8.5%) | 51 (14.4%) | 0.013 |
| Total RBCs transfusion (U) | 164 | 289 | 0.019 |
| FFP transfusion, no. (%) | 96 (27.1%) | 109 (30.8%) | 0.281 |
| Total FFP transfusion (ml) | 63770 | 78660 | 0.225 |
| Platelet transfusion, no. (%) | 25 (7.1%) | 18 (5.1%) | 0.271 |
| Total Platelet transfusion (U) | 261 | 205.7 | 0.432 |
| Postoperative RBCs transfusion | |||
| Postoperative in 24 h, no. (%) | 72 (20.4%) | 63 (17.8%) | 0.389 |
| Postoperative in 24 h [median (IQR); U] | 0 (0 to 0) | 0 (0 to 0) | 0.407 |
| >24 h after surgical start, no. (%) | 24 (6.8%) | 25 (7.1%) | 0.882 |
| >24 h after surgical start [median (IQR); U] | 0 (0 to 0) | 0 (0 to 0) | 0.881 |
| Postoperative FFP transfusion | |||
| Postoperative in 24 h, no. (%) | 90 (25.5%) | 93 (26.3%) | 0.797 |
| Postoperative in 24 h [median (IQR); ml] | 0 (0 to 230) | 0 (0 to 200) | 0.914 |
| Postoperative after 24 h, no. (%) | 7 (2.0%) | 7 (2.0%) | 1.000 |
| >24 h after surgical start [median (IQR); ml] | 0 (0 to 0) | 0 (0 to 0) | 0.996 |
| Postoperative Platelet transfusion | |||
| Postoperative in 24 h, no. (%) | 10 (2.8%) | 9 (2.5%) | 0.816 |
| Postoperative in 24 h [median (IQR); U] | 0 (0 to 0) | 0 (0 to 0) | 0.802 |
| Postoperative after 24 h, no. (%) | 1 (0.3%) | 2 (0.6%) | 0.624# |
| >24 h after surgical start [median (IQR); U] | 0 (0 to 0) | 0 (0 to 0) | 0.561 |
| Total Perioperative Allogeneic transfusions | |||
| RBC transfusion, no. (%) | 98 (27.7%) | 96 (27.1%) | 0.866 |
| RBCs transfusion (U) | 0 (0 to 2) | 0 (0 to 2) | 0.300 |
| FFP transfusion, no. (%) | 153 (43.2%) | 157 (44.4%) | 0.762 |
| FFP transfusion (ml) | 0 (0 to 730) | 0 (0 to 630) | 0.876 |
| Platelet transfusion, no. (%) | 35 (9.9%) | 28 (7.9%) | 0.355 |
| Platelet transfusion (U) | 0 (0 to 0) | 0 (0 to 0) | 0.380 |
| Postoperative HCT [median (SD); %] | 32 ± 5 | 32 ± 4 | 0.464 |
RBCs red blood cells, FFP fresh frozen plasma, HCT hematocrit, ANH acute normovolemic hemodilution
Postoperative outcomes (n = 354)
| Outcomes | Propensity-matched | ||
|---|---|---|---|
| ANH | Non-ANH |
| |
| Pulmonary infection | |||
| no | 329 (93.2%) | 313 (88.7%) | |
| yes | 24 (6.8%) | 40 (11.3%) | 0.036 |
| Death | |||
| no | 350 (99.2%) | 351 (99.4%) | |
| yes | 3 (0.8%) | 2 (0.6%) | 1.000# |
| Prolonged wound healing | |||
| no | 332 (94.1%) | 341 (96.6%) | |
| yes | 21 (5.9%) | 12 (3.4%) | 0.109 |
| Stroke | |||
| no | 352 (99.7%) | 350 (99.2%) | |
| yes | 1 (0.3%) | 3 (0.8%) | 0.624# |
| AF | |||
| no | 237 (86.8%) | 233 (85.7%) | |
| yes | 36 (13.2%) | 39 (14.3%) | 0.696 |
| Resternotomy for postoperative bleeding | |||
| no | 349 (98.9%) | 350 (99.2%) | |
| yes | 4 (1.1%) | 3 (0.8%) | 1.000# |
| AKI | |||
| no | 245 (74.0%) | 241 (74.6%) | |
| yes | 86 (26.0%) | 82 (25.4%) | 0.862 |
| Stage1 | 63 (73.3%) | 59 (71.9%) | |
| Stage2 | 15 (17.4%) | 18 (22.0%) | |
| Stage3 | 8 (9.3%) | 5 (6.1%) | |
| Ventilation [mean (SD); hours] | 17 ± 21 | 19 ± 29 | 0.239 |
| ICU [mean (SD); days] | 4.4 ± 2.4 | 4.2 ± 3.1 | 0.254 |
| LOS [mean (SD); days] | 12 ± 9 | 12 ± 10 | 0.708 |
AF atrial fibrillation, AKI acute kidney injury, ANH acute normovolemic hemodilution, ICU intensive care unit, LOS length of hospital stay